ACE2 expression in adipose tissue is associated with COVID-19 cardiometabolic risk factors and cell type composition

Julia S. El-Sayed Moustafa^{1*}, Anne U. Jackson^{2*}, Sarah M. Brotman^{3*}, Li Guan^{4*}, Sergio Villicaña¹, Amy L. Roberts¹, Antonino Zito^{1,5,6}, Lori Bonnycastle⁷, Michael R. Erdos⁷, Narisu Narisu⁷, Heather M. Stringham², Ryan Welch², Tingfen Yan⁷, Timo Lakka^{8,9,10}, Stephen Parker⁴, Jaakko Tuomilehto^{11,12,13}, Francis S. Collins⁷, Päivi Pajukanta¹⁴, Michael Boehnke², Heikki A. Koistinen^{15,16,17}, Markku Laakso^{18,19}, Mario Falchi¹, Jordana T. Bell¹, Laura J. Scott^{2**}, Karen L. Mohlke^{3**} and Kerrin S. Small^{1**}

- 1. Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
- 2. Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, MI, USA
- 3. Department of Genetics, University of North Carolina, Chapel Hill, NC, USA
- 4. Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, USA
- 5. Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA
- 6. Department of Genetics, Harvard Medical School, Boston, MA 02115; USA
- 7. National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
- 8. Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio, Finland
- 9. Kuopio Research Institute of Exercise Medicine, Kuopio, Finland
- 10. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland
- 11. Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki,
- 12. Department of Public Health, University of Helsinki, Helsinki, Finland
- 13. Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia
- 14. Department of Human Genetics and Institute for Precision Health, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- 15. Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
- 16. University of Helsinki and Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
- 17. Minerva Foundation Institute for Medical Research, Helsinki, Finland
- 18. Department of Medicine, University of Eastern Finland, Kuopio, Finland.
- 19. Kuopio University Hospital, Kuopio, Finland

^{*} These authors contributed equally to this work.

^{**}Joint senior authors

Corresponding authors:

Julia S. El-Sayed Moustafa Department of Twin Research and Genetic Epidemiology, King's College London, London, UK Email: julia.el-sayed moustafa@kcl.ac.uk

Kerrin S. Small Department of Twin Research and Genetic Epidemiology, King's College London, London, UK Email: kerrin.small@kcl.ac.uk

Abstract

COVID-19 severity has varied widely, with demographic and cardio-metabolic factors increasing risk of severe reactions to SARS-CoV-2 infection, but the underlying mechanisms for this remain uncertain. We investigated phenotypic and genetic factors associated with subcutaneous adipose tissue expression of Angiotensin I Converting Enzyme 2 (ACE2), which has been shown to act as a receptor for SARS-CoV-2 cellular entry. In a meta-analysis of three independent studies including up to 1,471 participants, lower adipose tissue ACE2 expression was associated with adverse cardio-metabolic health indices including type 2 diabetes (T2D) and obesity status, higher serum fasting insulin and BMI, and lower serum HDL levels (P<5.32x10⁻⁴). ACE2 expression levels were also associated with estimated proportions of cell types in adipose tissue; lower ACE2 expression was associated with a lower proportion of microvascular endothelial cells ($P=4.25 \times 10^{-4}$) and higher macrophage proportion (P=2.74x10⁻⁵), suggesting a link to inflammation. Despite an estimated heritability of 32%, we did not identify any proximal or distal genetic variants (eQTLs) associated with adipose tissue ACE2 expression. Our results demonstrate that at-risk individuals have lower background ACE2 levels in this highly relevant tissue. Further studies will be required to establish how this may contribute to increased COVID-19 severity.

Main

Since December 2019 the COVID-19 pandemic has swept across the world, with over

sixteen million confirmed cases worldwide and almost 700,000 fatalities reported at

the time of writing¹. A distinctive and challenging aspect of COVID-19 is its wide

disease spectrum, with vast differences observed in both symptom range and severity,

as well as clinical progression, across those affected2. While initial reports focused on

respiratory symptoms^{3,4}, it is now clear that severe COVID-19 also has a substantial

effect on the cardiovascular and renal systems⁵. Marked differences in clinical

outcomes have been associated with demographic features including age and sex, as

well as comorbidities including cardiovascular disease, diabetes, and obesity^{2,4,5}. An

urgent need exists to improve understanding of the mechanisms by which such

predisposing factors increase susceptibility to severe reactions to SARS-CoV-2

infection.

ACE2 has become central in understanding COVID-19 pathogenesis, as SARS-CoV-

2 employs ACE2 as a receptor for cellular entry^{6,7}. ACE2 is expressed in a number of

tissues and cell types^{6,8-11}. It is currently unclear whether higher ACE2 levels are

harmful or beneficial in the context of COVID-19. Higher levels of ACE2 may on the

one hand provide additional targets enabling viral invasion of ACE2-expressing cells,

however higher ACE2 also has beneficial effects in regulation of the renin-angiotensin

system (RAS), which is critical for controlling hypertension and associated cardio-

metabolic disorders^{12,13}. Extensive reports of adverse cardio-metabolic effects in

rodent models with decreased or ablated ACE2 levels support the critical role of ACE2

4

in a healthy cardiovascular system¹⁴.

Obesity, characterised by an excess of fat mass¹⁵, is one of the strongest reported risk factors for severe COVID-19^{2,5}, but the underlying mechanism of this increased risk remains unclear. Adipose tissue, composed of adipocytes, immune and vascular endothelial cells, is both an energy reservoir and an endocrine organ, and secretes a wide variety of hormones, cytokines and chemokines^{16,17}. In the Genotype-Tissue Expression (GTEx) resource of gene expression in 54 tissues, adipose tissue ranks among the highest sites of ACE2 expression in the body^{11,18} (Supplementary Figure 1). Several potential mechanisms have been proposed for the contribution of adipose tissue to COVID-19 clinical severity^{19,20}, and its influence may in fact be multi-factorial. Adipose tissue has been shown to act as a viral reservoir for numerous viruses, including SARS-CoV and type A influenza^{21,22}, and may contribute to prolonged viral shedding²³. Critically, ACE2 in adipose tissue plays an important role in balancing of the local adipose RAS, disruption of which may then lead to wider systemic effects on the renin-angiotensin system²⁰. Adipose tissue is also a prime candidate contributor to the widely-reported cytokine storm characteristic of severe COVID-19^{19,20}. Most importantly, obesity is a potentially modifiable COVID-19 risk factor, and deeper understanding of the contribution of adipose tissue to COVID-19 severity, as well as to cardio-metabolic risk more generally, may better inform therapeutic strategies, and motivate policies supporting healthy weight maintenance programmes.

Given the dual relevance of ACE2 in maintenance of cardio-metabolic health generally as well as its role as SARS-CoV-2 receptor, it is of interest to explore whether ACE2 expression is associated with demographic and phenotypic traits associated with COVID-19 severity. There have been several reports supporting variation in ACE2 expression across tissues, and early evidence of differences in associations across

samples and even between cell types within the same tissue 11,24. In this study, we investigated the phenotypic and genetic factors associated with ACE2 gene expression in subcutaneous adipose tissue from 1,471 participants from three cohorts^{25–27}, representing the largest meta-analysis of adipose tissue gene expression studies to date. We quantified adipose ACE2 expression levels in bulk RNA-Seq data from TwinsUK^{25,28,29} (765 female mono- and dizygotic twins), 426 males from the Metabolic Syndrome in Men (METSIM) study²⁶, and 149 Finnish males and 131 Finnish females from the Finland-United States Investigation of NIDDM Genetics (FUSION) Tissue Biopsy Study²⁷. The cohorts differ in country of origin, male:female composition, age distribution and underlying ascertainment criteria (Table 1). Study participants ranged in age from 35 to 85 years, with variation between studies (Table 1 and Supplementary Figure 2). While TwinsUK and METSIM are representative of the UK and Kuopio Finland populations, the FUSION study design was enriched for individuals with abnormal glycaemic indices at time of biopsy.

We hypothesised that the true effect sizes of ACE2 gene expression-phenotypic associations may vary between cohorts differing in demographic characteristics, and due to technical and methodological differences between the studies. We therefore assessed association of ACE2 gene expression with demographic and phenotypic traits in each of the TwinsUK, METSIM and FUSION studies, adjusting for age and BMI, and then conducted a random-effect inverse-variance-weighted meta-analysis combining association results from the three studies. Results of meta-analysis of the three studies showed consistency in association signals across cohorts for some traits, but heterogeneity for others.

Adipose tissue *ACE2* expression was relatively low across all three cohorts (Table 1, Supplementary Figures 3 and 4). In our meta-analysis, lower adipose tissue *ACE2* expression levels were associated with higher serum fasting insulin (β [95% CI] = -0.12[-0.18, -0.05]; $P = 5.32 \times 10^{-4}$), and higher body mass index (BMI) (β [95% CI]= -0.10[-0.16, -0.04]; $P = 3.94 \times 10^{-4}$) (Figure 1 and Supplementary Table 1). Consistent with the association observed for BMI, obese participants had lower adipose tissue *ACE2* expression compared to normal-weight controls (β [95% CI]= -0.34[-0.50, -0.17]; $P = 4.81 \times 10^{-5}$) (Figure 1 and Supplementary Table 1).

TwinsUK included a subset of individuals diagnosed with T2D prior to biopsy collection. Within TwinsUK, T2D status was associated with lower adipose tissue *ACE2* expression compared to normoglycaemic controls (β [95% CI] = -0.84[-1.21, -0.47]; $P = 9.14 \times 10^{-6}$). No association was observed with fasting glucose in our study (P>0.05) (Figure 1 and Supplementary Table 1).

Lower *ACE2* expression was strongly associated with lower serum HDL cholesterol (β [95% CI] = 0.16[0.10, 0.21]; $P = 1.92 \times 10^{-7}$) (Figure 1 and Supplementary Table 1). Association of total serum triglycerides with adipose tissue *ACE2* expression showed heterogeneity between studies (I²=73.24; Q-test P = 0.01). Results of meta-analysis of all three studies showed only nominally-significant association between lower *ACE2* expression and higher triglyceride levels (β [95% CI] = -0.13[-0.25, 0.00]; $P = 4.15 \times 10^{-2}$), but this association was not significant after multiple testing correction (MTC threshold $P < 3.33 \times 10^{-3}$). In TwinsUK, lower *ACE2* expression in adipose tissue was strongly associated with higher total triglyceride levels (β [95% CI] = -0.23[-0.31, -0.14]; $P = 1.63 \times 10^{-7}$). Adipose tissue *ACE2* expression was not associated with serum

LDL cholesterol, nor with systolic or diastolic blood pressure (P > 0.05) in our study (Figure 1 and Supplementary Table 1).

Severity of COVID-19 disease presentation has been associated with age^{2–5}. Upon meta-analysis, higher adipose ACE2 expression levels were nominally associated with older age (β [95% CI] = 0.15 [0.05, 0.26]; P = 5.23x10⁻³), but not significant after multiple testing correction (Figure 1 and Supplementary Table 1). However, we observed heterogeneity in age effects between studies (Heterogeneity I²=71.38; Cochrane's Q-test P = 0.02) potentially driven by differences in the age distribution of studies. In the study with the largest age range, TwinsUK (38-85 years), higher adipose tissue ACE2 expression was strongly associated with older age (β [95% CI] = 0.25[0.17, 0.32]; $P = 6.31 \times 10^{-9}$). Higher ACE2 expression in older individuals observed in adipose tissue was consistent with previous reports of age-dependent ACE2 expression in nasal epithelium³⁰. However, in skin of the same TwinsUK participants lower ACE2 expression was associated with increased age (β [95% CI]= -0.23[-0.31, -0.14]; $P = 4.77x10^{-7}$), supporting heterogeneity of effects between tissues¹¹ (Supplementary Figure 5).

Located on the X chromosome, ACE2 has been shown to escape from X inactivation³¹. Association of ACE2 expression with sex was assessed only in the FUSION study. which included both males and females. Consistent with reports from GTEx¹¹, ACE2 expression was nominally higher in females in FUSION (β [95% CI] = 0.32[0.02, 0.61]; P = 0.037), but this difference was not significant after multiple testing correction (Figure 1 and Supplementary Table 1).

Adipose tissue consists of multiple cell types, gene expression of all of which is represented in bulk RNA-Seq data, and to our knowledge, it is still unclear which adipose cell types are responsible for expression of ACE2. We therefore assessed the relationship between ACE2 expression in subcutaneous adipose tissue and estimated adipose tissue cell type proportions. Consistent with the differences in biopsy methods employed, significant heterogeneity in cell type composition was observed between the three studies (Figure 2). Despite these differences, higher proportion of microvascular endothelial cells (MVEC) was associated with higher ACE2 expression (β [95% CI]= 0.15[0.07, 0.23]; P = 4.25x10⁻⁴), suggesting microvascular endothelial cell subpopulations contribute to ACE2 expression levels in adipose tissue (Figure 2 and Supplementary Table 2). Conversely, lower ACE2 expression was associated with higher macrophage proportion (β [95% CI] = -0.18 [-0.26, -0.09]; P = 2.74x10⁻⁵) (Figure 2 and Supplementary Table 2). Increased macrophage infiltration in adipose tissue has been associated with a pro-inflammatory state³². ACE2 expression was not associated with adipocyte proportion (P > 0.05; Figure 2 and Supplementary Table 2).

To establish whether phenotypic associations with *ACE2* expression were simply reflecting differences in adipose tissue cell type composition³³, we conducted sensitivity analyses including the estimated proportion of MVECs as a covariate in our models. While strength of association was attenuated for some phenotypes, the associations were largely robust to adjustment for MVEC proportion (Supplementary Table 3), suggesting phenotypic associations were not driven solely by differences in the proportions of *ACE2*-expressing cell types. Furthermore, correlation patterns between phenotypic traits including age and each of adipose tissue *ACE2* expression and MVEC proportions were notably different (Supplementary Figure 6). In contrast,

phenotypic associations were notably attenuated upon inclusion of both MVEC and

macrophage proportions as covariates in our models (Supplementary Table 4),

potentially due to adipose tissue macrophage proportions reflecting inflammatory

status.

There is evidence that genetic factors may influence risk of severe COVID-19³⁴. Using

the twin structure of TwinsUK, we estimated the heritability of adipose tissue ACE2

expression to be 0.32[95% CI = 0.14-0.50] (Figure 3). To identify proximal genetic

variants associated with ACE2 expression, we conducted a cis-eQTL meta-analysis

of all three studies including 1,151 participants for whom chromosome X genotype

data were available (See Methods section). No genetic variants within 1Mb of ACE2

were associated with adipose tissue ACE2 expression after correction for multiple

testing (minimum $P = 2.58 \times 10^{-3}$ at chrX:15263126 A/C) (Figure 3 and Supplementary

Table 5). This result was consistent with the absence of an ACE2 cis-eQTL signal in

numerous GTEx tissues¹¹. We also assessed whether any trans-eQTL variants

genome-wide were associated with ACE2 expression levels; no variants were

associated with ACE2 expression at genome-wide significance (Figure 3 and

Supplementary Table 6). Neither adjustment for MVEC proportion nor meta-analysis

of males and females separately identified significant cis- or trans-eQTLs in our

analyses.

Finally, we explored epigenetic effects on ACE2 expression using matched adipose

tissue methylation data, measured on the Illumina Infinium HumanMethylation450

BeadChip for 540 participants in TwinsUK³⁵. Similar to our eQTL results, no proximal

methylation probes were associated with genetic variants in cis or trans. In addition,

no proximal methylation probes were associated with adipose ACE2 expression (minimum P = 0.048 at cg08559914), indicating that methylation at measured sites in our sample does not appear to be a reliable proxy for adipose tissue gene expression at this locus (Supplementary Figure 7).

Taken together, the analyses presented here show that ACE2 expression in adipose tissue is associated with multiple COVID-19 comorbidities. We have shown that lower adipose tissue ACE2 expression was associated with diabetes and obesity status, increased serum fasting insulin and triglyceride levels, BMI, and with increased macrophage infiltration in adipose tissue, a marker of inflammation³². ACE2 expression was positively correlated with HDL levels, age and adipose tissue MVEC proportion. As previously noted for ACE2 associations reported in other tissues³⁶, given its association with adipose tissue cell type proportions, it remains unclear to what extent these associations are mediated through differences in underlying cell type composition. While sensitivity analyses adjusting for MVEC cell type proportion estimates suggested that the ACE2 expression-trait associations were robust, estimation of cell type composition from bulk RNA-Seq data in non-blood tissues remains in its infancy. Adipose tissue single-cell RNA sequencing (scRNA-Seq) datasets will be critical to fully address this question. Furthermore, as seen for its association with age in the TwinsUK sample, ACE2 expression-trait associations may differ between tissues, supporting the need for caution in their interpretation and extrapolation. The contrast between our observation that adipose tissue ACE2 levels were positively correlated with age -another strong risk factor for severe COVID-19yet negatively correlated with COVID-19 cardio-metabolic risk factors may reflect the multi-systemic nature of COVID-19, and may indicate that the various COVID-19 risk factors, including age, may be mediated through different tissues and underlying mechanisms of susceptibility. Despite evidence of heritability of adipose tissue *ACE2* expression levels and our meta-analysis sample size, we did not yet identify cis- or trans-eQTLs associated with adipose *ACE2* expression. Increased sample sizes may be needed to detect genetic factors influencing expression of *ACE2* in this important tissue.

Overall, our results suggest that lower adipose tissue expression of ACE2 is associated with multiple adverse cardio-metabolic health indices, all of which are risk factors for severe COVID-19^{2,4,5}. Increasing evidence suggests that COVID-19 severity may be modulated by widespread microvascular damage and increased predisposition to thrombotic events^{37–39}, in which ACE2, and the RAS system more widely, may play a critical role. Adipose tissue is an active endocrine organ which secretes hormones, chemokines and cytokines that contribute to regulation of inflammatory and immune responses 16,17. Given the association of ACE2 expression with cardio-metabolic risk factors for severe COVID-19, it is intriguing to consider whether low levels of adipose ACE2 expression may contribute to COVID-19 progression in at-risk individuals. SARS-CoV infection has been shown to reduce ACE2 levels post-infection^{40–43}. Our observation that individuals suffering from recognised severe COVID-19 comorbidities may have lower pre-infection ACE2 levels in some tissues may support the theory that low ACE2 levels in at risk-individuals are then reduced further upon SARS-CoV-2 infection, contributing to the dysregulation of the RAS characteristic of severe COVID-19⁴⁴. Further studies will be needed to clarify the contribution of adipose tissue ACE2 expression levels to COVID-19 and beyond.

Materials and methods

Sample collection

TwinsUK

Gene expression data, measured by RNA-Seq, was available for up to 804 female

twins from the TwinsUK cohort⁴⁵. Sample collection and processing in TwinsUK has

been reported fully elsewhere⁴⁵. Briefly, punch biopsies were taken from a sun-

protected area of the abdomen from each participant. Subcutaneous adipose tissue

and skin were separated and RNA extracted for each tissue type. Lymphoblastoid cell

lines (LCL) were generated from blood samples collected at the time of biopsy. Gene

expression in adipose tissue (n=765), skin (n=706), LCLs (n=804) and whole blood

(n=389) was measured by RNA sequencing, as previously described⁴⁵.

METSIM

Sample collection and processing has previously been reported for the population-

based METSIM cohort, composed of 10,197 males of Finnish ancestry⁴⁶. RNA-

sequencing of subcutaneous adipose tissue for 426 male participants collected near

the umbilicus by needle biopsy was generated as previously described²⁶.

FUSION

331 living FUSION participants were recruited from Helsinki, Savitaipale, and Kuopio,

as previously described²⁷. Adipose tissue biopsies were obtained and processed from

296 of the 331 participants following the same general protocol as previously

described for the concurrently-obtained muscle biopsies²⁷. Biopsies were taken under

local anaesthetic, by surgical scalpel from abdominal subcutaneous fat 5-10 cm lateral

of the umbilicus, cleaned of blood and other visible non-adipose tissue, and rinsed

with 0.9% sodium chloride. Adipose RNA-sequencing was performed as described for

muscle RNA-sequencing²⁷.

RNA-Seq data processing

TwinsUK and METSIM

RNA-Seq reads were aligned to the hg19 reference genome using STAR⁴⁷ version

2.4.0.1 (TwinsUK) and 2.4.2a (METSIM), and quality control conducted as previously

described^{26,48}. Gene-level quantification was conducted using the quan function from

QTLtools⁴⁹ and Gencode version 19⁵⁰.

FUSION

RNA-Seg reads were aligned to the hg19 reference genome using procedures as

described in Scott et al²⁷. Six outlier samples were excluded based on read coverage

at the 3' end of the gene body, and five outliers based on gene diversity. The allelic

RNA-Seg read count distribution was compared to known sample genotypes using

verifyBamID⁵¹ and two contaminated samples were identified and removed, as well

as one pair of sample swaps corrected. Reported sex of the remaining samples was

verified by matching the sex inferred using XIST gene expression and the mean Y

chromosome gene expression. Linear regression of gene expression as a function of

age, sex, batch, and RIN was performed in addition to performing PCA on the gene

expression residuals. The minimum number of PCs were selected to explain 20% of

the variance in gene expression. The PCs were transformed to z-scores and did not

observe any sample outliers with |z-score| >5. Finally, one non-Finnish subject and

one from each of two first-degree relative pairs were removed. A total of 280 samples

14

were retained in the analysis.

Gene inclusion and normalization

For all three studies, RNA-Seg gene expression data were filtered to retain only genes

with 5 or more counts per million (CPMs) in greater than or equal to 25% of individuals

in each study. Trimmed mean of M-values normalisation was applied to gene counts⁵²,

and TMM-normalised gene CPMs were then inverse-normalised prior to all

downstream analyses (inverse-normalized ACE2).

Estimation of adipose tissue cell type proportions

Adipose tissue cell type proportions were estimated in TwinsUK using CIBERSORT⁵³,

as previously described³³. Estimated cell types included in our analysis were

adipocytes, microvascular endothelial cells (MVEC) and macrophages.

To estimate the proportions of adipose and blood cell types in the adipose biopsies

from the FUSION and METSIM studies, a reference transcriptome was created using

RNA-Seq of whole blood (GEO accession GSE67488⁵⁴), and of four types of purified

adipose cells (adipocytes, macrophages, CD4+ T cells, and microvascular endothelial

cells) described in Glastonbury et al³³. For the FUSION study, reference transcriptome

reads were aligned to the hg19 reference genome using the same read mapping and

quality control procedure as used for the FUSION adipose RNA-Seg data²⁷.

Blood/cell-type proportions for each FUSION adipose sample were estimated using

the unmix function from DESeq2 v1.18.1⁵⁵. A gene expression signature matrix was

constructed and blood/cell-type proportions were estimated for each METSIM adipose

15

sample using CIBERSORT⁵³.

Phenotypic association analyses

For quantitative phenotypic trait association analyses, in TwinsUK we excluded a subset of participants who had not fasted on the day of biopsy and for whom biochemical measurements were not matched to the day of biopsy, or for whom fasting and time of visit covariates were not available (n=161). Participants with T2D were excluded from all analyses in all studies except those modelling association of diabetes status with *ACE2* expression.

We assessed association between ACE2 gene expression levels (Gencode ID ENSG00000130234.6) and phenotypic traits including age, BMI, serum fasting insulin, fasting plasma glucose, serum HDL and LDL cholesterol, total triglycerides, systolic and diastolic blood pressure, obesity, T2D status (TwinsUK only) and sex (FUSION only). For obesity status, cases (TwinsUK: n=119; METSIM: n=67; FUSION: n=68) were defined as participants with BMI ≥ 30kg/m², while controls (TwinsUK: n=259; METSIM: n=140; FUSION: n=79) were defined as participants with BMI < 25kg/m². In TwinsUK, established T2D case status (n=31) was defined through longitudinal patient self-reports, and longitudinal records of elevated fasting plasma glucose (≥ 7mmol/l) and serum fasting insulin levels. In this study, individuals were defined as T2D controls (n=567) if they had no longitudinal records of elevated fasting plasma glucose nor serum fasting insulin, as well as no self-reports of diabetes. Individuals with insulin resistance, defined as participants with longitudinally-elevated serum fasting insulin levels (>60pmol/l) with fasting plasma glucose levels consistently below 6.0mmol/l (n=130), were excluded from T2D association analyses. In FUSION, study participants underwent a 2-h, four-point OGTT after a 12-h overnight fast, and T2D, IFG, IGT and NGT status was assigned per WHO criteria⁵⁶. We also assessed association of *ACE*2

expression with adipose tissue estimated cell type proportions, specifically each of

macrovascular endothelial cell, macrophage and adipocyte proportions, estimated as

described above.

We performed rank-based inverse normal transformation of all quantitative phenotypic

traits. Association between ACE2 gene expression levels and each phenotypic trait

was assessed by fitting linear mixed effects models using the Imer function from the

Ime4 package⁵⁷ (TwinsUK) or the Im function (METSIM and FUSION) in R⁵⁸ version

3.5.1 (TwinsUK and METSIM) or version 3.6.3 (FUSION). Inverse normalised ACE2

expression was treated as a continuous dependent variable, and each phenotypic trait

in turn was treated as an independent fixed effect.

Covariates included in the TwinsUK study were: age, BMI (for all phenotypes except

BMI and obesity), number of hours fasted, sample median transcript integrity number

(TIN)⁵⁹, median insert size, and mean GC content included as fixed effects. Random

effects included were date of RNA sequencing, morning versus afternoon visit time,

RNA extraction batch, primer index, family and zygosity. Family and zygosity are both

random effects that describe the family a twin belongs to, and their clonality (MZ/DZ

status). Each family identifier is specific to a twin pair, and each zygosity label is

identical for each pair of MZ twins, while individual DZ co-twins are each given a

unique zygosity label. In TwinsUK, the full model was then compared to a null model

where the phenotypic trait of interest was omitted, using a 1 degree of freedom

17

ANOVA.

Covariates included in the METSIM study were: age, BMI (for all phenotypes except

BMI and obesity), blood cell type proportion, read deletion size, mean read insertion

size, TIN, and sequencing batch.

Covariates included in the FUSION study were: age, sex, BMI (for all phenotypes

except BMI and obesity), collection site, blood cell type proportion, four genetic PCs,

mean GC content, median read insertion size, RNA integrity number (RIN), TIN, and

sequencing batch included as fixed effects. In the FUSION study, which included both

males and females, analyses were also performed in males and females separately,

excluding the sex covariate in the models.

Sensitivity analyses were conducted for all three studies, including estimated MVEC

cell type proportion, then both estimated MVEC and macrophage cell type proportions,

as an additional covariate(s) in the models above.

Meta-analysis of phenotypic associations with adipose tissue ACE2 expression

We conducted a random-effects inverse-variance weighted meta-analysis of up to

1,237 participants, combining ACE2 gene expression-phenotype association results

from the TwinsUK, METSIM and FUSION studies (See Supplementary Tables 1-4 for

trait-specific numbers of participants). Meta-analysis was conducted for 13 out of 15

traits using the rma function (restricted maximum likelihood method) from the metafor

package⁶⁰ in R version 3.5.1⁵⁸. Association of T2D with ACE2 was assessed in

TwinsUK only, as it was the only study with participants with established T2D at time

of biopsy. Association of ACE2 expression with sex was assessed in FUSION only,

given that the TwinsUK and METSIM studies included only females or males,

respectively, to avoid biasing of estimates that may result from confounding by study-

specific technical differences.

A multiple testing correction threshold of $P < 3.33 \times 10^{-3}$, calculated using a Bonferroni

correction for 15 traits, was used to assess significance of phenotypic associations

with ACE2 expression.

ACE2 heritability analyses

Heritability of gene expression levels of ACE2 was assessed in the TwinsUK sample

using an ACE model to decompose variance in gene expression residuals, adjusted

for technical covariates, into additive genetic effects (A), common environmental

effects shared by both mono- and dizygotic co-twins (C) and unique environmental

influences (E). ACE models were fitted using the twinlm function from the mets

package^{61,62} in R version 3.5.1⁵⁸. Heritability models included age as a covariate.

Genotype data, imputation and quality control

In TwinsUK, imputed genotype data and adipose tissue gene expression data were

available for 722 females. TwinsUK, METSIM and FUSION genotype data were

generated as previously described^{63,46,64}, and were imputed to the Haplotype

Reference Consortium panel (HRC version 1.1). Variants with MAF < 0.01, imputation

 $R^2 < 0.5$, and Hardy Weinberg $P < 1 \times 10^{-6}$ were excluded. HRC-imputed genotype

data were used for genome-wide association analysis of ACE2 expression for all

19

studies.

For ACE2 ciseQTL analyses, in TwinsUK, HRC-imputed genotypes (HRC version 1.1)

were available only for autosomes. Chromosome X genotypes were called from low

depth 7x sequencing as part of the UK10K project, as previously described⁶⁵ and were

available for 490 of 765 TwinsUK participants for whom adipose tissue gene

expression data were available. 39 participants were excluded from cis-eQTL

analyses due to skewing of X chromosome inactivation⁶⁶. In METSIM and FUSION,

HRC-imputed genotypes (HRC version 1.1) were available for all chromosomes

including the X in all participants^{46,64}. In males, chromosome X variants were coded

as 0,1 alleles.

Cis-eQTL analyses of adipose tissue ACE2 expression

We defined proximal genetic variants to be those within 1Mb on either side of the

ACE2 transcription start site. For TwinsUK, we adjusted gene counts for family

structure using a linear mixed effects model including family and zygosity as random

effects. In each study, cis-eQTL analyses were conducted using QTLTools, including

BMI and 40 PEER factors⁶⁷ as covariates.

Genome-wide association analysis of *ACE2* expression

We conducted a GWAS of ACE2 expression, in order to identify trans-eQTLs that may

modulate ACE2 expression. All variants greater than 1Mb from the ACE2 transcription

start site were included in this analysis. For TwinsUK, ACE2 rank inverse normalised

gene counts were first adjusted for family structure and technical covariates using a

linear mixed effects model including mean GC content and median insert size as fixed

effects and sample processing date, primer index, RNA extraction batch, family and

zygosity as random effects. GWAS of ACE2 expression rank inverse normalised

expression (METSIM and FUSION) or residuals as described above (TwinsUK) was then conducted using QTLTools⁴⁹ for all studies. Covariates included age, BMI, sample median TIN⁵⁹ and genotyping chip as covariates (TwinsUK). For METSIM, covariates included age, BMI, read deletion size, mean read insertion size, sample median TIN, sequencing batch, and blood proportion as covariates. For FUSION, covariates included were sex, age, BMI, RIN, median TIN, collection site, batch, four genetic PCs, mean GC content, and median insert size as covariates. FUSION also performed sex-stratified GWAS using the same covariates except sex.

Meta-analysis of ACE2 expression cis-eQTL and GWAS association results

Cis-eQTL and genome-wide association analyses of adipose tissue ACE2 expression from the TwinsUK, METSIM and FUSION cohorts were meta-analysed using the sample-size based method implemented in METAL⁶⁸. Meta-analysis was limited to variants present in a minimum of two out of the three studies (cis-eQTL: N_{subjects} = 1,157, N_{variants} = 2,669 variants; *ACE*2 expression GWAS: N_{subjects} = 1,428, N_{variants} = 7,652,879 variants). Due to the fact that the ACE2 gene is located on the X chromosome, we conducted meta-analyses including all participants, as well as sexstratified.

The threshold for significance of association of cis-eQTL variants with ACE2 expression was $P < 6.94 \times 10^{-5}$, calculated using the EigenMT approach to estimate the number of independent tests in the region in the largest sample (TwinsUK). 721 principal components were found to account for > 99% of the variance in the variants tested. For the identification of trans-eQTL variants associating with ACE2 expression, a genome-wide threshold of significance of $P < 5.0 \times 10^{-8}$ was used.

ACE2 methylation analyses in TwinsUK

DNA methylation patterns were profiled with the Illumina Infinium HumanMethylation450 BeadChip for 540 adipose tissue biopsy samples, as previously described³⁵. Methylation β-values were pre-processed with the ENmix package⁶⁹ within the R environment and inverse-normalised. After filtering out samples skewed for X-chromosome inactivation, there were 495 samples for downstream analyses. For GWAS of DNA methylation levels in CpGs annotated within the ACE2 gene (i.e. methylation quantitative trait loci, meQTLs) DNA methylation values were first adjusted for covariates in a linear mixed-effects model with fixed effect factors including smoking, age and bisulfite conversion efficiency, and zygosity, and random effects including position on array and family. MeQTL analysis was then performed on the resulting residuals using Matrix eQTL⁷⁰ in both cis (2Mb window, with a total of 325 samples with available genotypes) and in trans for all variants greater than 1Mb either side of the CpGs annotated within the ACE2 gene. The association between ACE2 expression and proximal methylation probes was carried out in Matrix eQTL, using methylation and ACE2 gene expression residuals adjusted for technical and family confounders as previously described (as well as smoking status for methylation data). The methylation-expression association models included age, BMI, T2D status and MVEC estimation as covariates.

Correlation of phenotypic traits

The correlations between phenotypic traits were assessed in TwinsUK, which was the largest study included in our analyses. Phenotypic trait correlations were assessed using a Spearman correlation in unrelated participants from TwinsUK (n=441), in R version 3.5.1⁵⁸.

Accession codes

TwinsUK RNA-Seq data are deposited in the European Genome-phenome Archive (EGA) under accession EGAS00001000805. METSIM RNASeq data have been deposited in the Gene Expression Omnibus (GEO) under accession GSE135134. The

dbGaP accession number for the FUSION Tissue Biopsy Study is phs001048.v2.p1.

Code availability statement

All custom scripts, implementing the analyses described in the methods section, are available upon request.

Display items

Table 1: Descriptive statistics of study participants. Quantitative traits are reported as median[1st-3rd quartiles]. Statistics for all traits are calculated including only nondiabetic participants. ACE2 expression levels are reported as TMM-adjusted counts per million (CPMs).

	TwinsUK	METSIM	FUSION
N [% female]	765[100%]	426[0%]	280[47%]
Age (years)	59[52-65]	54 [51-59]	60[55-65]
BMI (kg/m²)	25.6[23.3-28.8]	26.2 [24.6-28.6]	26.7[24.2-28.8]
Serum fasting insulin (pmol/l)	38.0[25.0-59.5]	35.4 [25.2-55.8]	43.8[28.8-59.1]
Fasting plasma glucose (mmol/l)	4.9[4.6-5.2]	5.7[5.4-6.0]	5.9[5.6-6.3]
Serum HDL (mmol/l)	1.80[1.53-2.14]	1.45 [1.20-1.70]	1.44[1.20-1.70]
Serum LDL (mmol/l)	3.18[2.57-3.82]	3.43 [2.96-3.96]	3.34[2.78-3.89]
Serum triglycerides (mmol/l)	0.96[0.72-1.33]	1.17 [0.88-1.62]	1.17[0.89-1.56]
Systolic BP (mmHg)	128[118-139]	132[123-141]	133[121-145]
Diastolic BP (mmHg)	78[71-85]	87[81-93]	82[76-87]
Adipose tissue ACE2 expression (TMM-adjusted CPMs)	1.86[1.16-3.05]	1.25[0.82-1.83]	1.15[1.07-2.62]




Figure 1: Associations of adipose tissue ACE2 expression levels with cardiometabolic and demographic traits in the TwinsUK, METSIM and FUSION studies. Squares with error bars represent the standardised β coefficients and their 95% confidence intervals for association of ACE2 expression levels with each of the traits (derived from linear/linear mixed effects regression models), with the metaanalysis effect sizes and 95% confidence intervals (random-effects meta-analysis)

shown as black diamonds. N represents the sample size for each analysis. a) serum fasting insulin, b) fasting plasma glucose, c) BMI d) serum HDL cholesterol, e) serum LDL cholesterol, f) serum total triglycerides, g) systolic blood pressure, h) diastolic blood pressure, i) age, j) obesity status. Association of ACE2 expression with k) type 2 diabetes status in TwinsUK and I) sex in the FUSION study. Boxplots (k-I) display the median and inter-quartile range (IQR), with whiskers corresponding to +/- 1.5*IQR.




Figure 2: Adipose tissue estimated cell type proportions and their association with *ACE2* expression levels across the TwinsUK, METSIM and FUSION studies.

Density plots of estimated cell type proportions of a) microvascular endothelial cells (MVEC), b) macrophages, c) adipocytes in each of the TwinsUK, METSIM and FUSION studies. Vertical dashed lines correspond to the study mean. d-f) Association of adipose tissue *ACE2* expression levels with estimated d) MVEC, e) macrophage and f) adipocyte proportions. Squares with error bars represent the standardised β coefficients and their 95% confidence intervals for association of *ACE2* expression levels with each of the traits (derived from linear/linear mixed effects regression models), with the meta-analysis effect sizes and 95% confidence intervals (random-effects meta-analysis) shown as black diamonds. N represents the sample size for each analysis.




Figure 3: Genetic factors influencing adipose tissue expression of *ACE2*. a) Heritability of *ACE2* expression, assessed using an ACE model in the TwinsUK study. *ACE2* expression was partitioned into that which could be explained by (A) additive genetic effects (h²), common environment (C) and unique environment (E). Error bars show the 95% confidence intervals. b) Regional plot of *ACE2* cis-eQTL associations in 1,157 participants, within 1Mb either side of the *ACE2* transcription start site. c) Manhattan plot of genome-wide association study meta-analysis of adipose tissue

ACE2 expression in 1,428 participants. For plots b-c, the x-axis denotes chromosomal position, and the y-axis is -log10(P-value). The red line indicates the threshold for genome-wide significance ($P < 5x10^{-8}$).

References

- Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track 1. COVID-19 in real time. The Lancet Infectious Diseases 20, 533–534 (2020).
- 2. Docherty, A. B. et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 10, 2020.04.23.20076042 (2020).
- 3. Chen. N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet **395**, 507–513 (2020).
- 4. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497–506 (2020).
- 5. Intensive care national audit & research centre. ICNARC report on COVID-19 in critical care - 04 April 2020. 1-16 (2020).
- 6. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
- 7. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280.e8
- 8. Ziegler, C. G. K. et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell (2020). doi:10.1016/j.cell.2020.04.035
- 9. Seow, J. J. W. et al. scRNA-seq reveals ACE2 and TMPRSS2 expression in TROP2+ Liver Progenitor Cells: Implications in COVID-19 associated Liver Dysfunction. bioRxiv 2020.03.23.002832 (2020). doi:10.1101/2020.03.23.002832
- Fan, C., Li, K., Ding, Y., Lu, W. L. & Wang, J. ACE2 Expression in Kidney and 10. Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. medRxiv 2020.02.12.20022418 (2020). doi:10.1101/2020.02.12.20022418
- 11. He, Y. Tissue specific expression and genetic regulation of SARS-CoV-2 receptors ACE2 and TMPRSS2. Available at: https://medium.com/@yuanhe716/tissue-specific-expression-and-geneticregulation-of-sars-cov-2-receptors-ace2-and-tmprss2-d75d76bf45fb. (Accessed: 13th June 2020)
- 12. Schmieder, R. E., Hilgers, K. F., Schlaich, M. P. & Schmidt, B. M. Reninangiotensin system and cardiovascular risk. Lancet 369, 1208–1219 (2007).
- 13. Tikellis, C. & Thomas, M. C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int. J. Pept. **2012**, (2012).
- 14. Crackower, M. A., Sarao, R., Oliveira-dos-Santos, A. J., Da Costa, J. & Zhang, L. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002). doi:10.1038/nature00786
- Arner, P. & Spalding, K. L. Fat cell turnover in humans. *Biochem. Biophys.* 15. Res. Commun. 396, 101-104 (2010).
- 16. Scheja, L. & Heeren, J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nature Reviews Endocrinology 15, 507–524 (2019).
- 17. Makki, K., Froquel, P. & Wolowczuk, I. Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines. 2013, 12 (2013).

- 18. Aguet, F. et al. Genetic effects on gene expression across human tissues. Nature (2017). doi:10.1038/nature24277
- Malavazos, A. E., Corsi Romanelli, M. M., Bandera, F. & Iacobellis, G. 19. Targeting the Adipose Tissue in COVID-19. *Obesity* oby.22844 (2020). doi:10.1002/oby.22844
- 20. Rvan. P. M. & Caplice. N. M. Is Adipose Tissue a Reservoir for Viral Spread. Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019? Obesity oby.22843 (2020). doi:10.1002/oby.22843
- 21. Bouwman, J. J. M., Diepersloot, R. J. A. & Visseren, F. L. J. Intracellular infections enhance interleukin-6 and plasminogen activator inhibitor 1 production by cocultivated human adipocytes and THP-1 monocytes. Clin. Vaccine Immunol. (2009). doi:10.1128/CVI.00166-09
- 22. Gu, J. & Korteweg, C. Pathology and pathogenesis of severe acute respiratory syndrome. American Journal of Pathology 170, 1136–1147 (2007).
- 23. Maier, H. E. et al. Obesity increases the duration of influenza a virus shedding in adults. J. Infect. Dis. (2018). doi:10.1093/infdis/jiy370
- 24. Muus, C. et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv 2020.04.19.049254 (2020). doi:10.1101/2020.04.19.049254
- 25. Moavyeri, A., Hammond, C. J., Hart, D. J. & Spector, T. D. The UK adult twin registry (twinsUK resource). Twin Res. Hum. Genet. 16, 144-149 (2013).
- 26. Raulerson, C. K. et al. Adipose Tissue Gene Expression Associations Reveal Hundreds of Candidate Genes for Cardiometabolic Traits. Am. J. Hum. Genet. (2019). doi:10.1016/j.ajhg.2019.09.001
- Scott, L. J. et al. The genetic regulatory signature of type 2 diabetes in human 27. skeletal muscle. Nat. Commun. (2016). doi:10.1038/ncomms11764
- 28. Grundberg, E. et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084-9 (2012).
- 29. Buil, A. et al. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet. 47, 88–91 (2015).
- 30. Bunyavanich, S., Do, A. & Vicencio, A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA - Journal of the American Medical Association (2020). doi:10.1001/jama.2020.8707
- 31. Tukiainen, T. et al. Landscape of X chromosome inactivation across human tissues. Nature (2017). doi:10.1038/nature24265
- 32. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. (2003). doi:10.1172/JCI200319246
- Glastonbury, C. A., Couto Alves, A., El-Sayed Moustafa, J. S. & Small, K. S. 33. Cell-Type Heterogeneity in Adipose Tissue Is Associated with Complex Traits and Reveals Disease-Relevant Cell-Specific eQTLs. Am. J. Hum. Genet. 104, 1013-1024 (2019).
- 34. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 28, 715-718 (2020).
- Grundberg, E. et al. Global analysis of dna methylation variation in adipose 35. tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am. J. Hum. Genet. (2013). doi:10.1016/j.ajhg.2013.10.004

- 36. Patel, A. B. & Verma, A. Nasal ACE2 Levels and COVID-19 in Children. JAMA - Journal of the American Medical Association (2020). doi:10.1001/jama.2020.8946
- 37. Han, H. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin. Chem. Lab. Med. 58, 1116-1120 (2020).
- 38. Lodigiani, C. et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb.* Res. 191, 9-14 (2020).
- 39. Klok, F. A. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).
- 40. Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005).
- 41. Haga, S. et al. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc. Natl. Acad. Sci. U. S. A. (2008). doi:10.1073/pnas.0711241105
- 42. Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature (2005). doi:10.1038/nature03712
- 43. Zheng, Y. Y., Ma, Y. T., Zhang, J. Y. & Xie, X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology (2020). doi:10.1038/s41569-020-0360-5
- 44. Alghatrif, M., Cingolani, O. & Lakatta, E. G. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights from Cardiovascular Aging Science. JAMA Cardiology (2020). doi:10.1001/jamacardio.2020.1329
- 45. Buil, A. et al. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet. 47, 88–91 (2015).
- 46. Civelek, M. et al. Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic Traits. Am. J. Hum. Genet. 100, 428–443 (2017).
- 47. Dobin, A. et al. STAR: Ultrafast universal RNA-seg aligner. Bioinformatics 29. 15–21 (2013).
- 48. Glastonbury, C. A. A. et al. Adiposity-Dependent Regulatory Effects on Multitissue Transcriptomes. Am. J. Hum. Genet. 99, 567–579 (2016).
- 49. Delaneau, O. et al. A complete tool set for molecular QTL discovery and analysis. Nat. Commun. 8, 15452 (2017).
- Frankish, A. et al. GENCODE reference annotation for the human and mouse 50. genomes. Nucleic Acids Res. 47, 767 (2019).
- 51. Jun, G. et al. Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. Am. J. Hum. Genet. 91, 839-848 (2012).
- 52. Chen, Y., Mccarthy, D., Ritchie, M., Robinson, M. & Smyth, G. K. edgeR: differential expression analysis of digital gene expression data User's Guide.
- 53. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453-457 (2015).
- 54. Tabassum, R. et al. Omic personality: Implications of stable transcript and methylation profiles for personalized medicine. Genome Med. 7, 88–88 (2015).
- 55. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, (2014).
- 56. WHO. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: report of a WHO/IDF consultation. World Health Organization (2006).

perpetuity.

It is made available under a CC-BY 4.0 International license .

- 57. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using Ime4. *J. Stat. Softw.* **67**, 51 (2015).
- 58. R Development Core Team. R: A Language and Environment for Statistical Computing. *R Found. Stat. Comput. Vienna Austria* **0**, {ISBN} 3-900051-07-0 (2013).
- 59. Wang, L. *et al.* RSeQC: quality control of RNA-seq experiments. *Bioinformatics* **28**, 2184–2185 (2012).
- 60. Viechtbauer, W. Conducting meta-analyses in R with the metafor. *J. Stat. Softw.* **36**, 1–48 (2010).
- 61. Scheike, T. H., Holst, K. K. & Hjelmborg, J. B. Estimating heritability for cause specific mortality based on twin studies. *Lifetime Data Anal.* **20**, 210–233 (2014).
- 62. Holst, K. K., Scheike, T. H. & Hjelmborg, J. B. The liability threshold model for censored twin data. *Comput. Stat. Data Anal.* **93**, 324–335 (2016).
- 63. Hysi, P. G. *et al.* A genome-wide association study for myopia and refractive error identifies a susceptibility locus at 15q25. *Nat. Genet.* **42**, 902–905 (2010).
- 64. Leland Taylor, D. *et al.* Integrative analysis of gene expression, DNA methylation, physiological traits, and genetic variation in human skeletal muscle. *Proc. Natl. Acad. Sci. U. S. A.* **166**, 10883–10888 (2019).
- 65. Walter, K. *et al.* The UK10K project identifies rare variants in health and disease. *Nature* **526**, 82–89 (2015).
- 66. Zito, A. *et al.* Heritability of skewed X-inactivation in female twins is tissue-specific and associated with age. doi:10.1038/s41467-019-13340-w
- 67. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. *Nat. Protoc.* **7**, 500–7 (2012).
- 68. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinforma. Appl. NOTE* **26**, 2190–2191 (2010).
- 69. Xu, Z., Niu, L., Li, L. & Taylor, J. A. ENmix: A novel background correction method for Illumina HumanMethylation450 BeadChip. *Nucleic Acids Res.* (2016). doi:10.1093/nar/gkv907
- 70. Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics* **28**, 1353–8 (2012).

Acknowledgements

KSS acknowledges funding from the Medical Research Council (MR/M004422/1 and MR/R023131/1). TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. The FUSION and METSIM studies were supported by US National Institutes of Health (NIH) grants U01DK062370, 1-ZIA-HG000024, R01DK093757, R01DK072193, P01HL28481, and Academy of Finland Grants 271961, 272741 and 258753. SMB was supported in part by a grant from the National Institute of General Medical Sciences under award 5T32 GM007092 and acknowledges the Global Partnership Award and UNC Global for travel funds. SV is supported by the National Council of Science and Technology of Mexico (CONACYT).

The authors acknowledge use of the research computing facility at King's College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy's & St. Thomas' NHS Foundation Trusts, and partfunded by capital equipment grants from the Maudsley Charity (award 980) and Guy's & St. Thomas' Charity (TR130505). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, King's College London, or the Department of Health and Social Care. The authors thank Dr. Jörg Saßmannshausen and Dr Lukasz Zalweski from the Rosalind support team for their computational support.

Author contributions

J.S.E-S.M. and K.S.S. conceived and designed the study. J.S.E-S.M. conducted

statistical analyses of the TwinsUK study data and meta-analyses. A.U.J. and L.G.

conducted statistical analyses of the FUSION study data. S.M.B. conducted statistical

analyses of the METSIM study data. J.S.E-S.M., A.U.J., L.G., S.M.B., L.J.S., K.L.M.

and K.S.S. interpreted the data. S.V. performed analysis of the TwinsUK methylation

data, supervised by J.T.B. MF advised on statistical analyses. A.L.R., A.Z., L.B.,

M.R.E., N.N., H.M.S., R.W., T.Y., T.L., S.P., J.T., F.S.C., P.P., M.B., H.A.K. and M.L.

participated in sample collection/data generation/data processing. J.S.E-S.M., A.U.J.,

L.G., S.M.B., A.L.R, L.J.S., K.L.M. and K.S.S. wrote the manuscript. All co-authors

provided critical feedback and approved the manuscript.

Competing interests statement

The authors declare no competing interests.

Ethics declaration

The TwinsUK project was approved by the ethics committee at St Thomas' Hospital

London, where all the biopsies were carried out. Volunteers gave informed consent

and signed an approved consent form prior to the biopsy procedure. Volunteers were

supplied with an appropriate detailed information sheet regarding the research project

and biopsy procedure by post prior to attending for the biopsy. The FUSION study was

approved by the coordinating ethics committee of the Hospital District of Helsinki and

Uusimaa, and written informed consent was obtained from all participants. The

METSIM study was approved by the Ethics Committee of the University of Eastern

Finland and Kuopio University Hospital in Kuopio, Finland, and written informed consent was obtained from all participants.

Supplementary information

See supplementary information file and supplementary tables. Full summary statistics for meta-analysis of adipose tissue ACE2 expression GWAS (Supplementary Table 6 of this manuscript) available from the authors upon request.